基质金属蛋白酶-9和组织金属蛋白酶抑制剂-1在食管鳞癌中的表达

目的探讨基质金属蛋白酶-9（MMP-9）和组织金属蛋白酶抑制剂-1（TIMP-1）在食管鳞癌中的表达及其临床意义。方法用免疫组化和Western blot法分别检测41例食管鳞癌患者的癌及相应正常组织中MMP-9和TIMP-1的表达变化。结果食管鳞癌组织中MMP-9阳性表达率与食管癌淋巴结及静脉转移有关；MMP-9的阳性表达率与表达量均显著高于TIMP-1；MMP-9和TIMP-1的表达呈负相关。结论MMP-9与食管鳞癌的侵袭转移有关，其机制可能与食管鳞癌组织中的MMP-9／TIMP-1平衡失调有关；MMP-9与TIMP-1联合检测有助于食管鳞癌生物学行为的判断。     

转化生长因子-β1对绒癌JEG-3细胞MMP-9 mRNA及TIMP-1 mRNA表达的影响

目的 探讨转化生长因子-β1(TGF-β1)不同浓度和作用时间对绒癌JEG-3细胞基质金属蛋白酶-9基因(MMP-9 mRNA)及基质金属蛋白酶抑制剂-1基因(TIMP-1 mRNA)表达的影响.方法 先分别用TGF-β1 0、100、200 ng/ml作用于绒癌JEG-3细胞,48 h收获细胞;再以TGF-β1 100 ng/ml分别与JEG-3细胞作用0、12、24、48、72 h;最后用RT-PCR技术检测TGF-β1不同浓度和作用时间收获JEG-3细胞的MMP-9 mRNA及TIMP-1 mRNA表达.结果 随TGF-β1浓度升高和作用时间延长,各收获细胞的MMP-9 mRNA及TIMP-1 mRNA表达均明显升高,且MMP-9 mRNA与 TIMP-1 mRNA比值均＞1(P＜0.01或＜0.05).结论 在一定浓度和作用时间内,外源性TGF-β1可促进绒癌JEG-3细胞MMP-9 mRNA及TIMP-1 mRNA表达.     

MMP-9、TIMP-1和NF-κB在甲状腺乳头状癌中的表达及意义

采用免疫组织化学和原位杂交方法检测157例甲状腺乳头状癌和30例甲状腺乳头状瘤组织中基质金属蛋白酶9(MMP-9)、金属蛋白酶组织抑制因子1(TIMP-1)及NF-κB的表达.结果显示甲状腺乳头状癌中MMP-9及NF-κB的蛋白及mRNA表达阳性率均明显高于乳头状瘤(均P<0.01).MMP-9及NF-κB蛋白和mRNA在甲状腺乳头状癌随着病理分级增高而显著增加(P<0.01);并且颈部淋巴结有转移者均高于无转移者(P<0.01).而TIMP-1蛋白及mRNA阳性表达率与MMP-9阳性表达率相反.     

胃癌组织中MMP-9mRNA、TIMP-1mRNA的表达变化及意义

目的观察基质金属蛋白酶（MMP）-9及其抑制剂（TIMP一1）在胃癌组织中的表达变化,并探讨两者在胃癌发生、发展中的作用。方法采用逆liT—PCR法检测43份胃癌组织、35份癌旁组织和8份胃溃疡组织中MMP-9和TIMP-1的mRNA表达,分析两指标表达的相关性及与胃癌临床病理特征的关系。结果胃癌组织中MMP一9mRNA、TIMP一1mRNA表达均显著高于癌旁组织和胃溃疡组织,尤以T。级、有淋巴结转移、Ⅲ期者为著（P均〈0．05）;MMP-9mRNA、TIMP一1mRNA表达均与胃癌患者性别、年龄、肿瘤大小及分化程度无关,与浸润深度、淋巴结转移及临床分期有关（P均〈0．05）。结论胃癌组织中MMP-9mRNA、TIMP一1mRNA的表达升高,且与肿瘤浸润、侵袭有关。     

鼻腔鳞状细胞癌组织中MMP-2、MMP-9、TIMP-1、TIMP-2的表达变化及意义

目的 观察鼻腔鳞状细胞癌组织中基质金属蛋白酶(MMP)-2、MMP-9及组织金属蛋白酶抑制剂(TIMP)-1、TIMP-2的表达变化,并探讨其意义.方法 鼻腔鳞状细胞癌患者45例(观察组),鼻窦炎或过敏性鼻息肉患者30例(对照组),采用免疫组化法检测各组MMP-2、MMP-9、TIMP-1、TIMP-2,分析各指标间及与鼻腔鳞状细胞癌临床病理特征的相关性.结果 观察组MMP-2、MMP-9、TIMP-1、TIMP-2阳性率分别为57.8％、62.2％、66.7％、73.3％,对照组分别为23.3％、13.3％、56.7％、26.7％,两组MMP-2、MMP-9、TMP-2比较P均＜0.05.MMP-2表达与鼻腔鳞状细胞癌TNM分期、淋巴结转移、分化程度有关(P均＜0.05),MMP-9、TIMP-2与鼻腔鳞状细胞癌TNM分期、分化程度有关(P均＜0.05).鼻腔鳞状细胞癌中MMP-2与TMP-2表达呈正相关(r=0.64,P＜0.05).结论 MMP-2、MMP-9及TIMP-2表达与鼻腔鳞状细胞癌的浸润、转移及预后密切相关.     

Angiopoietin-2,MMP-9和TIMP-1在胰腺癌中的表达及其与胰腺癌侵袭转移的关系

目的观察血管生成素-2(Ang-2),基质金属蛋白酶-9(MMP-9)及其组织抑制因子-1(TIMP-1)在胰腺癌中的表达,探讨3者的表达与胰腺癌侵袭转移间的关系及3者间的联系。方法应用免疫组化染色法检测40例胰腺癌患者癌组织,20例癌旁组织中Ang-2、MMP-9及TIMP-1的表达。结果胰腺癌组织中Ang-2、MMP-9及TIMP-1阳性表达率分别为45%,67·5%及47·5%,均显著高于癌旁组织中表达水平。结论Ang-2、MMP-9在胰腺癌的侵袭与转移过程中起重要作用,并且它们之间可能存在互相诱导或是协同效应,其共位表达可能作为判断预后的指标。TIMP-1的表达随胰腺癌浸润深度增加而减少。     

TIMP-1在哈萨克族食管癌组织中的表达及其意义

目的探讨基质金属蛋白酶组织抑制物-1（TIMP-1）在哈萨克族食管癌组织中的表达及其与临床病理特征的关系。方法采用RT—PCR检测48例哈萨克族食管癌切除标本与远端正常组织中TIMP-1mRNA表达水平,并分析其与临床病理特征的关系;采用Western blot对20例标本中TIMP-1蛋白表达进行检测。结果癌组织中TIMP-1mRNA表达远高于其远端正常组织（P〈0．05）;在临床早期病例中TIMP-1基因在癌组织及远癌正常组织中的差异亦具有统计学意义（P〈0．05）,蛋白表达与基因转录表达水平基本一致。TIMP-1mRNA表达在癌组织浸润深度、分化程度及有无淋巴结转移间差异无统计学意义。结论TIMP-1可能参与了哈萨克族食管癌发生的早期过程。     

TIMP-1和TIMP-2在原发性肝癌生长、浸润及转移中的作用

目的：了解基质金属蛋白酶组织抑制因子-1(tissue inhibitou of metalloproteinase-1，TIMP-1)和基质金属蛋白酶组织抑制因子-2(TIMP-2)mRNA及相关抗原在肝癌组织中的定位和表达状态，探讨TIMP-1和TIMP-2在肝癌组织生长、浸润及转移中所起的作用。方法：以TIMP-1和TIMP-2探针及单克隆抗体（McAb）为试剂，采用原位杂交技术及免疫组织化学法检测原发性肝癌、肝高分化腺癌的肝组织中TIMP-1和TIMP-2mRNA及相关抗原的表达，并与10例正常肝组织做对照。结果：20例原发性肝癌患者的肝组织中TIMP-1和TIMP-1mRNA及相关抗原表达的阳性率为90%;9例肝高分化腺癌的腺癌组织中无TIMP-1和TIMP-2mRNA及相关抗原的表达；10例正常肝组织中TIMP-1和TIMP-2mRNA及相关抗原表达均为阴性；TIMP-1和TIMP-2mRNA及相关抗原阳性信号呈现为棕黄色颗粒状，分布在肝细胞浆内，未见细胞核着色；无论是原发性肝癌癌组织还是癌周组织中,TIMP-1的表达强于TIMP-2的表达，癌周组织中TIMP-1和TIMP-2mRNA和相关抗原的表达与肝组织病理改变相关，即肝硬化者表达强，慢性肝炎者表达弱，正常肝组织无表达。结论：原发性肝癌的癌组织中存在TIMP-1和TIMP-2mRNA及相关抗原的表达，其表达强度可能与原发性肝癌的分型有关，它可能通过抑制MMP的活性使ECM降解减少从而阻止癌细胞通过基底膜移出而抑制肝癌细胞向周围浸润及转移。     

胃癌组织中KISS-1和MMP-9的表达及其意义

目的探讨肿瘤转移抑制基因K ISS-1及基质金属蛋白酶9（MMP-9）与胃癌侵袭、转移的关系,为研究胃癌的转移机制及治疗提供理论基础。方法采用逆转录聚合酶链反应（RT-PCR）检测36例胃癌组织及36例正常胃组织中K ISS-1 mRNA及MMP-9 mRNA的表达情况,分析其与胃癌患者各临床病理指标的关系及二者的相关性。结果 K ISS-1 mRNA在胃癌组织中的阳性表达率及表达水平均低于正常胃组织（P均〈0.01）,并且其低表达与淋巴结转移密切相关（P〈0.05）;MMP-9 mRNA在胃癌组织中的阳性表达率及表达水平均高于正常胃组织（P均〈0.05）,MMP-9 mRNA的高表达与癌的浸润深度和淋巴结转移密切相关（P均〈0.05）;K ISS-1与MMP-9表达呈负相关（P〈0.05）。结论 K ISS-1表达缺失和MMP-9过表达可能与胃癌的侵袭相关。     

血清基质金属蛋白酶-2与肝细胞癌根治性切除术后转移复发的关系

目的检测肝细胞癌(HCC)患者术前血清基质金属蛋白酶-2(MMP-2)水平以确定其与HCC根治性切除术后转移复发的关系。方法采用Cox风险分析模型对影响预后的临床指标进行分析以确定影响HCC切除术后生存时间的临床指标。同时,应用ELISA方法检测HCC患者术前血清MMP-2水平及northernbolt方法对24例相应肿瘤组织MMP-2mRNA表达水平进行定量分析。结果Cox风险分析模型显示肿瘤大小及肿瘤是否存在肝内播散是影响HCC切除术后生存时间的显著因素(P＝0.022和P＝0.040),并以此划分为高和低转移复发倾向组。根治性切除术后高转移复发倾向组HCC患者术前血清MMP-2显著高于根治切除术后低转移复发倾向组［(26.39±2.64)ng/ml对(24.86±1.95)ng/ml,P＜0.05］。非根治性切除组HCC患者术前血清MMP-2水平也显著高于根治性切除组HCC患者,(29.43±3.12)ng/ml对(25.72±2.45)ng/ml,P＜0.01。Northernblot显示,HCC患者血清MMP-2水平变化与其对应肿瘤组织MMP-2mRNA表达变化相一致。结论HCC患者术前血清MMP-2水平能反映HCC根治性切除术后转移复发倾向。HCC患者血清MMP-2水平升高是HCC细胞高表达MMP-2mRNA的结果。     

氯沙坦协同辛伐他汀对心力衰竭大鼠心室基质金属蛋白酶2、9及其组织抑制因子1、2基因表达的影响

目的 探讨心力衰竭(心衰)时心脏基质金属蛋白酶2(MMP-2)、9(MMP-9)及其组织抑制因子1(TIMP-1)、2(TIMP-2)基因表达及其与心肌纤维化的关系.方法 用降主动脉缩窄术建立心衰模型.SD大鼠随机分成6组.分别在氯沙坦5 mg/kg、辛伐他汀2 mg/kg以及两药合用(联合投药组)投药后1、3,5周动态测定左室舒张末期内径、左室收缩末期内径及左室后壁厚度、左室短轴缩短率.ELISA法检测B型利钠肽浓度.Masson染色观察心肌胶原情况.RT-PCR法检测心室MMP-2、MMP-9和TIMP-1、TIMP-2基因表达.结果 投药后5周各组胶原容积分数比较差异有统计学意义(P<0.01),投药各组较降主动脉缩窄(模型)组下降(P<0.05),尤其联合投药组下降更明显(P<0.01).MMP-2 mRNA和MMP-9 mBNA在投药各组与模型组差异无统计学意义(P>0.05);但TIMP-1 mRNA和TIMP-2 mRNA在投药各组明显低于模型组(P<0.01),联合投药组降低更明显(P<0.05).结论 心衰模型大鼠MMP-2 mRNA、MMP-9 mRNA和TIMP-1 mRNA、TIMP-2 mRNA表达升高可能是压力负荷大鼠心肌胶原含量增加的分子机制之一,氯沙坦、辛伐他汀以及联合投药均能下调TIMP-1 mRNA、TIMP-2 mRNA水平,缓解心肌重构,尤其联合投药组效果更明显.     

急性冠状动脉综合征患者巨噬细胞表达过氧化体增殖物激活型受体γ及炎症相关因子的变化

目的 探讨急性冠状动脉综合征患者外周血单核细胞源性巨噬细胞表达过氧化体增殖物激活型受体γ核因子κB、基质金属蛋白酶9和组织型基质金属蛋白酶抑制剂1的变化及其间的关系.方法 选取急性冠状动脉综合征患者48例、稳定型心绞痛患者22例为研究对象,抽取外周动脉血20 mL,分离单个核细胞,加巨噬细胞集落刺激因子培养得单核细胞源性巨噬细胞;用CD40配体刺激后,酶联免疫吸附法测定上清液中基质金属蛋白酶9和组织型基质金属蛋白酶抑制剂1浓度,逆转录聚合酶链反应检测过氧化体增殖物激活型受体γ、基质金属蛋白酶9和组织型基质金属蛋白酶抑制剂1 mRNA表达,免疫组织化学法检测核因子κ亚单位P65表达.结果 急性冠状动脉综合征组过氧化体增殖物激活型受体γ mRNA表达低于稳定型心绞痛组(0.24±0.04比0.39±0.06,P<0.001),核因子κ P65表达高于稳定型心绞痛组(0.42±0.06比0.27±0.02,P<0.001),基质金属蛋白酶9在上清液中的浓度及其mRNA表达明显高于稳定型心绞痛组(231.11±51.47μg/L比126.02±13.26μg/L和0.674±0.11比0.24±0.05,P<0.001),组织型基质金属蛋白酶抑制剂1在上清液中的浓度及其mRNA表达强度高于稳定型心绞痛组(139.80±31.54μg/L比112.25±12.68μg/L和0.42±0.09比0.33±0.06,P<0.05).过氧化体增殖物激活型受体γ mRNA表达与核因子κ P65和基质金属蛋白酶9的表达强度呈负相关(P<0.001),与组织型基质金属蛋白酶抑制剂1的表达强度不相关(P>0.05);核因子κ P65与基质金属蛋白酶9和组织型基质金属蛋白酶抑制剂1的表达强度呈正相关(P<0.001).结论 急性冠状动脉综合征患者外周血单核细胞源性巨噬细胞过氧化体增殖物激活型受体γ表达下调,核因子κ活性增强,基质金属蛋白酶9和组织型基质金属蛋白酶抑制剂1表达上调;过氧化体增殖物激活型受体γ可能通过调节核因子κ活性而调节基质金属蛋白酶9基因转录;但组织型基质金属蛋白酶抑制剂1表达可能不受过氧化体增殖物激活型受体γ调节.     

Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion

BACKGROUND/AIMS: Extracellular matrix-degrading matrix metalloproteinases (MMPs) are invariably up-regulated in epithelial cancers and are key agonists of angiogenesis, invasion and metastasis. Recent studies have shown high levels of various MMPs, including MT1-MMP, MMP-1, MMP-2 and MMP-9, and their involvement in tumor progression in human hepatocellular carcinoma (HCC). However, the expression and role of MT3-MMP in HCC remains unclear. METHODOLOGY: We examined the immunohistochemical expression of MT3-MMP in surgically resected HCCs (n=58), hepatitis C virus (HCV) and hepatitis B virus (HBV)-related chronic hepatitis (n=34) and cirrhosis (n=24). RESULTS: MT3-MMP expression was observed in all non-cancerous liver tissues. In HCCs, 52% (30/58) of patients showed high MT3-MMP expression while the remaining 48% (28/58) of patients showed low expression. A clinicopathological survey demonstrated a significant correlation between high MT3-MMP expression and capsular invasion of carcinoma (p = 0.034) although there was no correlation between high MT3-MMP expression in HCC and overall survival or disease-free survival. CONCLUSIONS: MT3-MMP was expressed not only in chronic hepatitis and liver cirrhosis, but also in HCC, and high MT3-MMP expression correlated significantly with capsular invasion of carcinoma.     

Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma

AIM: The expressive balance between matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor of metalloproteinase-1 (TIMP-1) plays a critical role in maintaining the degradation and synthesis of extracellular matrix. Loss of such balance is associated with invasion and metastasis of tumors. This study aimed to determine the expression of MMP-9 and TIMP-1 in gastric carcinoma, and the association of the expressive imbalance between MMP9 and TIMP-1 with the invasion and metastasis and prognosis of gastric carcinoma.METHODS: We used immunohistochemistry to determine the expressions of MMP-9, TTMP-1 and proliferating cell nuclear antigen Ki-67 in the gastric specimens taken from 256 patients with primary gastric carcinoma. The patients were followed-up for up to 96 months.RESULTS: No association between the expression of MMP9 and TIMP-1 and patients' sex and age, tumor size and location of gastric carcinoma was observed. The incidence of the positive expression of MMP-9 in cases with tumors invasion to muscularis propria and visceral peritoneum (70.13% and 69.09%, respectively) was significantly higher than that in cases with tumor invasion only to lamina propria or submucosa (42.50 %, P=0.0162). The positive correlation between MMP-9 expression and the depth of tumor invasion was observed (Pearson correlation coefficient=0.2129,P=0.016). Along with the increase of the metastatic station of lymph nodes, the incidence of the MMP-9 expression was increased by degrees; a positive correlation between them was observed (Pearson correlation coefficient=0.2910,P=0.0001). There was also a significant correlation between MMP-9 expression and the TNM stage in gastric carcinoma (Pearson correlation coefficient=0.3027, P＜0.0001). The incidence of MMP-9 expression in stage Ⅱ and Ⅲ/Ⅳ (75.00%and 76.15%, respectively) was significantly higher than those in stage Ⅰ (46.15 %, P＜0.0001). A negative correlation between TIMP-1 immunoreactivity and the depth of invasion,status of lymph node metastasis and TNM stage was observed (Pearson correlation coefficient =-0.1688, -0.3556and -0.3004, P=0.023, ＜0.0001 and ＜0.0001, respectively).Four types of co-expression of MMP-9 and TIMP-1 were observed; i.e. MMP-9 positive but T IMP-1 negative (n=115),both positive (n=52), both negative (n=62) and MMP-9negative but TIMP-1 positive (n=27). The frequency of serosal invasiveness was significant higher in patients with MMP-9 but without TIMP-1 expression than those with other types of the co-expression (P=0.0303). The incidence of lymph node metastasis was highest in patients with MMP-9but without TIMP-1 expression, and lowest in those with TIMP-1 but without MMP-9 expression (P＜0.0001). The survival rate in patients with MMP-9 but without TIMP-1expression was lower than that in those with TIMP-1 but without MMP-9 expression (P=0.0014).CONCLUSION: Our results in gastric carcinoma demonstrated a significant positive association of MMP-9 over-expression with proliferation of tumor cells, the depth of invasiveness,lymph node metastasis and TNM stage, suggesting MMP-9can serve as a molecular marker of tumor invasion and metastasis. We also demonstrate a significant negative relationship of TIMP-1 expression with the depth of invasiveness and lymph node metastasis, which provide a new idea in the tumor biological and genetic treatment.The interaction between MMP-9 and TIMP-1 in the processes of tumor invasion and metastasis is that MMP-9 mainly promotes tumor invasion and metastasis and TIMP-1 inhibits functions of MMP-9. The imbalance between MMP-9 and TIMP-1 expression may suggest the occurrence of tumor invasion and metastasis, predict poor prognosis. For patients with imbalanced MMP-9 and TIMP-1 expression, the optimal treatment scheme needs to be selected.     

Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9

Aim:  To investigate the status of Phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mammalian target of rapamycin (mTOR) pathway and its correlation with clinicopathological features and matrix metalloproteinase-2, -9 (MMP-2, 9) in human hepatocellular carcinoma (HCC).
Methods:  PTEN, Phosphorylated AKT (p-AKT), Phosphorylated mTOR (p-mTOR), MMP-2, MMP-9 and Ki-67 expression levels were evaluated by immunohistochemistry on tissue microarrays containing 200 HCCs with paired adjacent non-cancerous liver tissues. PTEN, MMP-2 and MMP-9 mRNA levels were determined by real-time RT-PCR in 36 HCCs. The relationships between PI3K/PTEN/AKT/mTOR pathway and clinicopathological factors and MMP-2, 9 were analyzed in HCC.
Results:  In HCC, PTEN loss and overexpression of p-AKT and p-mTOR were associated with tumor grade, intrahepatic metastasis, vascular invasion, TNM stage and high Ki-67 labeling index ( P  < 0.05). PTEN loss was correlated with p-AKT, p-mTOR and MMP-9 overexpression. Furthermore, PTEN and MMP-2, 9 mRNA levels were down-regulated and up-regulated in HCC compared with paired non-cancerous liver tissues, respectively ( P  < 0.01). PTEN, MMP-2 and MMP-9 mRNA levels were correlated with tumor stage and metastasis. There was an inverse correlation between PTEN and MMP-9 mRNA expression. However, PI3K/PTEN/AKT/mTOR pathway was not correlated with MMP-2.
Conclusions:  PI3K/PTEN/AKT/mTOR pathway, which is activated in HCC, is involved in invasion and metastasis through up-regulating MMP-9 in HCC.     

Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy

The matrix metalloproteinase system (MMP and the TIMP inhibitors), and the ADAM metalloproteinases, have roles in maintaining vascular plaque stability and the shedding of cell surface molecules, such as TNF-alpha and adhesion molecules; aspirin suppresses MMP expression and ADAM activity from some cell lines in vitro. In a randomised prospective controlled study, we examined peripheral venous monocyte MMP-9, TIMP-1 and ADAM mRNA levels, and protein expression, in subjects with type 2 diabetes (n=10) and controls (n=14) before and after oral aspirin therapy (150mg daily for 14 days) or no active intervention. Baseline monocyte TIMP-1 mRNA levels were significantly lower in the diabetes group (p=0.0014), although monocyte MMP-9 mRNA, and MMP-9 and TIMP-1 protein expression after culture did not differ significantly between groups. Plasma MMP-9 (p=0.027) and TIMP-1 (p=0.016) concentrations were significantly greater, and the ratio of plasma TIMP-1:MMP-9 concentrations significantly lower, in the diabetes group (p=0.023). ADAM mRNA levels did not differ significantly between groups and oral aspirin therapy had no significant effect on any variable. Type 2 diabetes is characterised by reduced monocyte TIMP-1 mRNA levels, and a lower plasma MMP-9 to TIMP-1 protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque. Monocyte ADAM mRNA levels do not differ between group and oral aspirin has no significant effect on these variables.     

基质金属蛋白酶及其抑制因子在脑胶质瘤侵袭性中的作用

目的分析基质金属蛋白酶(MM P)及其抑制因子(T IM P)的表达与脑胶质瘤恶性程度和侵袭性之间的关系。方法采用免疫组化SP法,测定76例不同级别胶质瘤(观察组)和10例正常脑组织对照组中MM P-2、MM P-3和T IM P-2蛋白表达。结果MM P-2蛋白表达水平与肿瘤的恶性程度呈正相关(P<0.01),不同级别的胶质瘤与正常脑组织比较,均有显著的差异(P<0.01)。胶质瘤中MM P-2和T IM P-2的表达水平之间呈明显负相关(r=-0.562,P<0.01)。MM P-3在正常脑组织与胶质瘤之间有显著差异性(P<0.05)。结论MM P-2的高表达与胶质瘤的恶性程度呈正相关;MM P-2与T IM P-2的平衡失调与胶质瘤的恶性程度和侵袭性密切相关,两者之间协同作用在胶质瘤的侵袭中有重要的意义。     

先天性心脏病并肺动脉高压患者肺组织中MMP-1、TIMP-1的表达研究

目的探讨基质金属蛋白酶1（MMP-1）及其抑制因子1（TIMP-1）在先天性心脏病（CHD）合并肺动脉高压（PH）发病机制中的可能作用。方法光镜下观察60例CHD患者肺小动脉形态,按照Heath-Edwards PH分级法分组,CHD无PH患者14例为对照组,CHD合并PHⅠ、Ⅱ、Ⅲ级共46例为实验组。采用免疫组化SP法和RT-PCR法分别测定患者肺组织MMP-1、TIMP-1蛋白及mRNA的表达情况。结果MMP-1 mRNA、TIMP-1 mRNA、TIMP-1／MMP-1、MMP-1蛋白、TIMP-1蛋白在对照组及各实验组间存在差异,且均与PH病理分级正相关（P〈0．05或〈0．01）。结论MMP-1、TIMP-1表达增高和二者比例失衡与CHD并发PH的形成与发展有关,可能是PH患者肺血管重构的发病机制之一。